“HER2 expression identifies dynamic functional states within circulating breast cancer cells.” Nature vol. 537,7618 (2016): 102-106. doi:10.1038/nature19328 Rugo, Hope S et al. “Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase...
然而,HER-2低表达或超低表达乳腺癌的治疗和预后评估在临床上仍存在争议。这一患者群体的确切定义、治疗响应和长期预后尚不明确,亟需更多的临床和科研工作来探索和阐明。 2023年8月, Frontiers in Oncology杂志发表了一项研究,题为《HER-...
乳腺癌的治疗决策通常基于传统的组织病理结果,临床上乳腺癌主要分为4种预后不同的亚型:Luminal A型、Luminal B型、人表皮生长因子受体2(human epidermal growth factor receptor 2, HER-2)阳性型和三阴型乳腺癌(triple-negative breast cancer, TNBC)。HER-2是乳腺癌重要的驱动基因和预后指标,也是抗HER-2药物治疗的...
Malignant neoplasm of breasttrastuzumab蛋白质酪氨酸激酶HER-2 is a tyrosine kinase receptor which is overexpressed in 20-25% of breast cancer patients and is associated with poor prognosis. Trastuzumab, a humanized monoclonal antibody directed against the HER-2 receptor, used alone or in combination ...
[4]Gelmon KA,Boyle FM,Kaufman B ,et al. Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31[J].J Clin Oncol,2015,33(1...
乳腺癌的治疗决策通常基于传统的组织病理结果,临床上乳腺癌主要分为4种预后不同的亚型:Luminal A型、Luminal B型、人表皮生长因子受体2(human epidermal growth factor receptor 2, HER-2)阳性型和三阴型乳腺癌(triple-negative breast cancer, TNBC)。HER-2是乳腺癌重要的驱动基因和预后指标,也是抗HER-2药物治疗...
2023年8月, Frontiers in Oncology杂志发表了一项研究,题为《HER-2 ultra-low breast cancer: exploring the clinicopathological features and prognosis in a retrospective study》,为我们提供了关于HER-2超低表达乳腺癌的深入分析。 研究方法: 本研究是一项回顾性队列研究,旨在探索HER-2超低表达乳腺癌患者的临床病...
Jordan, Nicole Vincent et al. “HER2 expression identifies dynamic functional states within circulating breast cancer cells.” Nature vol. 537,7618 (2016): 102-106. doi:10.1038/nature19328 Rugo, Hope S et al. “Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive ...
HER-2阳性晚期乳腺癌的预后随着一线和二线新抗HER2药物的应用而逐渐完善,HER2信号通路是主要的研究方向和治疗靶点,化疗联合抗HER2靶向治疗方案仍是解救HER-2阳性晚期乳腺癌的首选。 参考文献 [1]Ganz PA, Goodwin PJ. Breast cancer survivorship: where are we today? [J].Adv Exp Med Biol,2015,862:1-8. ...
HER2brain metastasesSeveral retrospective studies have illustrated the correlation between HER2 overexpression and increased risk of metastatic disease and poor prognosis in breast cancer. In a retrospective study, we evaluated the risk of brain metastases in these patients. Medical charts of 155 patients...